| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
|
Galffy, G.
|
|
|
8 |
3 |
p.
|
artikel
|
| 2 |
A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
|
Liu, B.
|
|
|
8 |
3 |
p.
|
artikel
|
| 3 |
Are you treating ypN0 patient with adjuvant abemaciclib?
|
Toss, A.
|
|
|
8 |
3 |
p.
|
artikel
|
| 4 |
Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology
|
Leone, A.G.
|
|
|
8 |
3 |
p.
|
artikel
|
| 5 |
Comments on “Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines”
|
Ibáñez, C.
|
|
|
8 |
3 |
p.
|
artikel
|
| 6 |
Controversies in upper GI oncology: first-line checkpoint inhibitor use in metastatic GEA: guided by PD-L1 CPS or not?
|
Petrillo, A.
|
|
|
8 |
3 |
p.
|
artikel
|
| 7 |
Corrigendum to “Canonical and uncanonical pathogenic germline variants in colorectal cancer patients by next-generation sequencing in a European referral center”
|
Poliani, L.
|
|
|
8 |
3 |
p.
|
artikel
|
| 8 |
Corrigendum to ‘Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers’
|
Samani, A.
|
|
|
8 |
3 |
p.
|
artikel
|
| 9 |
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases
|
Martin, P.
|
|
|
8 |
3 |
p.
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
8 |
3 |
p.
|
artikel
|
| 11 |
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial
|
Girard, N.
|
|
|
8 |
3 |
p.
|
artikel
|
| 12 |
Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study
|
Alouani, E.
|
|
|
8 |
3 |
p.
|
artikel
|
| 13 |
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer
|
Martini, G.
|
|
|
8 |
3 |
p.
|
artikel
|
| 14 |
Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer
|
Sapir, E.
|
|
|
8 |
3 |
p.
|
artikel
|
| 15 |
Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors
|
Zhou, F.
|
|
|
8 |
3 |
p.
|
artikel
|
| 16 |
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
|
Haanen, J.B.A.G.
|
|
|
8 |
3 |
p.
|
artikel
|
| 17 |
Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis
|
Wang, Y.
|
|
|
8 |
3 |
p.
|
artikel
|
| 18 |
Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping
|
Royer, B.
|
|
|
8 |
3 |
p.
|
artikel
|
| 19 |
In the literature: May 2023
|
Gambardella, V.
|
|
|
8 |
3 |
p.
|
artikel
|
| 20 |
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
|
Riecke, K.
|
|
|
8 |
3 |
p.
|
artikel
|
| 21 |
MiRNA dysregulation underlying common pathways in type 2 diabetes and cancer development: an Italian Association of Medical Oncology (AIOM)/Italian Association of Medical Diabetologists (AMD)/Italian Society of Diabetology (SID)/Italian Society of Endocrinology (SIE)/Italian Society of Pharmacology (SIF) multidisciplinary critical view
|
Natalicchio, A.
|
|
|
8 |
3 |
p.
|
artikel
|
| 22 |
Mutational landscape of SWI/SNF complex genes reveal correlation to predictive biomarkers for immunotherapy sensitivity in lung adenocarcinoma patients
|
Xu, H.
|
|
|
8 |
3 |
p.
|
artikel
|
| 23 |
Outcomes in breast cancer—does ethnicity matter?
|
Yap, Y.-S.
|
|
|
8 |
3 |
p.
|
artikel
|
| 24 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
|
Im, S.-A.
|
|
|
8 |
3 |
p.
|
artikel
|
| 25 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer
|
Yoshino, T.
|
|
|
8 |
3 |
p.
|
artikel
|
| 26 |
Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients
|
Giunco, S.
|
|
|
8 |
3 |
p.
|
artikel
|
| 27 |
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis ☆
|
Schettini, F.
|
|
|
8 |
3 |
p.
|
artikel
|
| 28 |
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
|
Le Cesne, A.
|
|
|
8 |
3 |
p.
|
artikel
|
| 29 |
Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis
|
Hyung, J.
|
|
|
8 |
3 |
p.
|
artikel
|
| 30 |
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial ☆
|
Stocker, G.
|
|
|
8 |
3 |
p.
|
artikel
|
| 31 |
Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer
|
Reissig, T.M.
|
|
|
8 |
3 |
p.
|
artikel
|
| 32 |
Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials
|
Mao, C.
|
|
|
8 |
3 |
p.
|
artikel
|
| 33 |
Table of Contents
|
|
|
|
8 |
3 |
p.
|
artikel
|
| 34 |
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
|
Ducreux, M.
|
|
|
8 |
3 |
p.
|
artikel
|
| 35 |
Timely course of SARS-CoV-2 infections and vaccinations in patients with hemato-oncological diseases: analysis of a real-life cohort
|
Mair, M.J.
|
|
|
8 |
3 |
p.
|
artikel
|
| 36 |
Tobacco cessation and the role of ESMO and medical oncologists: addressing the specific needs of cancer patients in times of the COVID-19 pandemic
|
Krech, R.
|
|
|
8 |
3 |
p.
|
artikel
|
| 37 |
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)
|
Pedrazzoli, P.
|
|
|
8 |
3 |
p.
|
artikel
|
Tijdschrift beschrijving